Tag: GLP-1

Lilly's Retatrutide Delivers Significant Weight Loss and A1C Reduction in Phase 3 Trial
Clinical Insights & Research Industry News Pharmacological Sleep Apnea

Lilly’s Retatrutide Delivers Significant Weight Loss and A1C Reduction in Phase 3 Trial

Lilly announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with type 2 diabetes and obesity or overweight. At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and […]

Continue Reading →
ŌURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options
Industry News Partnerships Pharmacological Technology

ŌURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options

ŌURA maker of the world’s most trusted smart ring, Oura Ring, and LillyDirect, Eli Lilly and Company’s digital health platform designed to connect people living with chronic conditions to the care, support, and prescribed medicines they need, today announced a collaboration enabling savings on the Oura Ring sizing kit. The […]

Continue Reading →
New SANSA Platform Enhancements & Cardiovascular Risk Data to be Presented at SLEEP 2026
Industry News Sleep Apnea Technology

Huxley Medical Expands SANSA Diagnostic Platform with Point-of-Care Enrollment and Additional Cardiovascular Risk Marker

Huxley Medical, a commercial-stage medical technology company expanding access to sleep apnea testing across health systems, cardiology, and primary care, introduced two additions to its SANSA® platform: SANSA GO™, a point-of-care enrollment model that enables clinics to dispense SANSA at patient visits, and hypoxic burden, an additional measure of cardiovascular […]

Continue Reading →